Prevalence of hyperuricemia among patients with non-communicable diseases in Ethiopia: a systematic review and meta-analysis Authors: Afewerk Habtamu, Zewudu Mulatie, Mikiyas Shemelis Achame, Sisay Desale, Saleamlak Sebsibe, Yonas Erkihun, Yeshimebet Kassa, Tesfaye Gessese, Mihreteab Alebachew, Mahider Shimelis Feyisa, Bruktawit Eshetu Published: 2026 ABSTRACT AbstractBackgroundHyperuricemia is one of the driving factors for the onset and progression of cardiovascular diseases, type 2 diabetes and hypertension. However, hyperuricemia is not measured regularly for these patients, and its worsening effect is underestimated. Thus, this systematic review and meta-analysis aimed to determine the pooled magnitude of hyperuricemia among patients with non-communicable diseases in Ethiopia.Methods and materialsThis systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Bibliographic databases and gray literature were extensively searched for relevant articles. Eligible articles were extracted using Microsoft Excel and exported to STATA version 17 software for statistical analysis. The pooled magnitude of hyperuricemia computed with Random-effects model. Furthermore, Sensitivity and subgroup analysis was done. Heterogeneity was determined using the I2 value. Funnel plot and Egger’s test statistics was used to assess publication bias.ResultsA total of 2292 patients from 8 studies were included in this systematic review and meta-analysis. The overall pooled prevalence of hyperuricemia among all patients with non-communicable diseases was 34.64% (95% CI: 29.27%, 40.02%). The prevalence of hyperuricemia among patients with cardiovascular diseases was 42.15% (95% CI: 38.08, 46.21), hypertension 34.79% (95% CI: 20.16, 49.42) and type 2 diabetes 30.87% (95% CI: 24.54, 37.20). The highest prevalence was found in Amhara region (36.73%, 95% CI: 26.12, 47.33), and the lowest was in Central Ethiopia (32.01%, 95% CI: 22.68, 41.34). The magnitude of hyperuricemia among females and males was 34.71% (95% CI: 27.79, 41.63) and 34.51% (95% CI: 29.91, 39.10) respectively. Hyperuricemia among participants aged < 45 years and > 45 years was 27.33% (95% CI: 19.82, 34.85) and 39.68% (95% CI: 34.08, 45.29) respectively.ConclusionThis systematic review and meta-analysis showed high prevalence of hyperuricemia among patients with non-communicable diseases. Therefore, regular monitoring of uric acid level is required to prevent its pathophysiological role in patients with non-communicable diseases.Systematic review registrationPROSPERO (2025: CRD420251174980).Supplementary InformationThe online version contains supplementary material available at 10.1186/s40842-026-00301-8.Keywords: Prevalence, Hyperuricemia, Non-communicable diseases, Systematic review, Meta-analysis Introduction Non-communicable diseases (NCDs) represent the leading cause of death worldwide, killing 41 million people each year-equivalent to 71–74% of all deaths globally. Among NCDs, the four top killers that together account for more than 80% of all premature NCDs deaths include cardiovascular diseases (17.9 million deaths annually), cancers (9.0 million), respiratory diseases (3.9 million), and diabetes (1.6 million) [1]. There has been a surge in the burden of NCDs in sub-Saharan Africa over the past two decades, driven by increasing incidence of cardiovascular risk factors such as unhealthy diets, reduced physical activity, hypertension, obesity, diabetes, dyslipidaemia, and air pollution [2, 3]. Hyperuricemia is a metabolic disorder marked by elevated serum uric acid concentrations in both extracellular fluids and tissues, coupled with impaired uric acid excretion [4]. The definition of hyperuricemia is SUA level ≥ 7.0 mg/dl (416.0 µmol/L) in males or ≥ 6.0 mg/dl (357.0 µmol/L) in females [5]. Uric acid plays a double-edged sword role in humans [6].Uric acid possesses antioxidant capabilities that combat free radicals and reactive oxygen species, thus preventing oxidative stress [7]. Uric acid, mediates the innate immune response, which can release inflammatory mediators and activate the renin-angiotensin system, inflammatory responses, oxidative stress, vascular endothelial dysfunction and insulin resistance [8, 9]. Several epidemiological and clinical studies have linked hyperuricemia to the development of various conditions, including chronic kidney disease, fatty liver disease, metabolic syndrome, hypertension, insulin resistance, obesity, type 2 diabetes mellitus, and cardiovascular disorders [4, 10–12]. Several studies have demonstrated a strong association between hyperuricemia and the development of Type 2 Diabetes Mellitus (T2DM). Elevated serum uric acid (SUA) has been identified as an independent predictor of insulin resistance and future diabetes, largely due to its role in endothelial dysfunction, oxidative stress, and chronic low-grade inflammation [13]. Hyperuricemia contributes to impaired nitric oxide availability, reduced glucose uptake in peripheral tissues, and β-cell dysfunction, all of which promote insulin resistance [14]. Epidemiological evidence consistently shows that individuals with higher SUA levels have an increased risk of progressing to T2DM, especially in the presence of obesity, hypertension, and metabolic syndrome [6, 15]. Epidemiological evidence consistently shows that hyperuricemia is independently associated with increased risks of coronary artery disease, heart failure, and stroke, even after adjusting for traditional risk factors such as hypertension, dyslipidemia, and diabetes [16, 17]. Elevated serum uric acid levels contribute to endothelial dysfunction, oxidative stress, and systemic inflammation, all of which play key roles in the pathogenesis of hypertension, atherosclerosis, and myocardial injury [18, 19]. Uric acid promotes vascular smooth muscle proliferation, impairs nitric oxide production, and enhances renal sodium retention, thereby elevating blood pressure and accelerating vascular damage [20, 21]. Studies showed that uric acid induces endothelial dysfunction by reducing nitric oxide availability, increases oxidative stress, and stimulates inflammation, all of which impair vascular relaxation [22, 23]. Uric acid also activates the renin–angiotensin–aldosterone system (RAAS) and promotes renal microvascular damage, leading to sodium retention and increased systemic vascular resistance [24]. Epidemiological studies consistently report that individuals with higher SUA levels have a significantly greater risk of developing hypertension, particularly among adolescents and young adults. Overall, the literatures indicated that hyperuricemia plays a significant role in the development and progression of T2DM, hypertension, and CVDs, making it an important target for risk assessment and potential intervention. Therefore, this systematic review and meta-analysis aimed to provide evidence regarding the magnitude of hyperuricemia among patients with non-communicable diseases in Ethiopia. Methods Protocol registration and guidelines The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines (PRISMA) [25] was followed accordingly to perform this systematic review and meta-analysis. Before the actual evidence collection, the protocol for this review was originally registered in the International Prospective Register of Systematic Reviews (PROSPERO) database with registration number CRD420251174980 available at: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251174980. Data source, search strategy and selection of studies All articles reporting the magnitude of hyperuricemia among patients with non-communicable diseases in Ethiopia were retrieved from many electronic databases, including PubMed/Medline, Epistimonikos, and Embase, through a methodical and thorough review of the body of current literature. Additionally, potentially eligible studies describing the prevalence of hyperuricemia among patients with non-communicable diseases in Ethiopia were retrieved using grey literature sources like Wiley Online Library, Science Direct, Research Gate, African Journal Online (AJOL), Google Scholar, and Web of Sciences. A snowball search was carried out utilizing the bibliographies of the indicated papers to incorporate more pertinent research that were overlooked during electronic database searches. In general, the search was carried out between November 01, 2025, and November 30, 2025. The formulated study question was “What is the prevalence of hyperuricemia among patients with non-communicable diseases in Ethiopia?“. Furthermore, the population (patients with non-communicable diseases), context (Ethiopia), and condition (hyperuricemia) included the CoCoPop framework. Medical Subject Headings (MeSH) terms and combination key words such as “prevalence,” “epidemiology,” “burden,” “magnitude,” “hyperuricemia,” “elevated uric acid,” “type 2 diabetes mellitus,” “cardiovascular diseases,” “hypertension,” and “Ethiopia” were used to access all relevant studies. The sophisticated search databases employed Boolean operators like “OR” and “AND” when needed. Endnote 25 software (Clarivate Analytics USA) was used to arrange the search results and eliminate duplicates. AH, MAB, and SD, three impartial reviewers, located the articles from databases and other sources and eliminated duplicates. The full texts of potentially eligible studies were then evaluated against inclusion criteria by three reviewers (YK, MS, and TG), confirmed by a third reviewer (MAS), and added to the extraction collection after three independent reviewers (ZM, YE, and SS) screened the titles and abstracts of all retrieved studies, which were then cross-checked by a third reviewer (BE). At each screening stage, disagreements were settled by the two reviewers reaching a consensus or by a third reviewer (BE) stepping in. Eligibility criteria Articles included in this systematic review and meta-analysis were those published in peer-reviewed journals or gray literature in English language and reported the prevalence of hyperuricemia among patients with NCDs (CVDs, T2DM and HTN). Moreover, all laboratory-based cross-sectional studies, in Ethiopia until November 30, 2025, were included. However, reviews, qualitative studies, author replies, letters to the editor, and commentaries which have incomplete data on the main hyperuricemia magnitude were excluded from this SRMA. Risk of bias assessment The quality of studies included in this SRMA was evaluated by three authors (AH, ZM and SS) using the Joanna Briggs Institute (JBI) quality appraisal tool designed for prevalence studies [26]. The critical appraisal checklist was used to evaluate the methodological quality of studies included in the SRMA. Finally, studies with an average quality score of ≥ 75% and ≥ 50% were considered to have very good and good quality respectively thus consequently included in the analysis. The evaluation involved screening studies at the title, abstract, and full text levels. A supplementary file provides further details on the critical appraisal process and scoring (Supplementary File 1). Outcome measurement The primary outcome variable of this systematic review and meta-analysis was the pooled prevalence of hyperuricemia among patients with non-communicable diseases in Ethiopia. Data extraction, synthesis and statistical analysis Three reviewers (TG, MAB, and BE) used a Microsoft Excel worksheet to extract data from qualifying papers. The authors’ names, publication year, region, study area, study period, setting, study design, approach, population type, laboratory diagnosis method, sample size, and number of hyperuricemia cases are all included in the extracted data. Missing or inconsistently reported covariates were collected from each study and excluded from analysis. The three reviewers carefully examined and confirmed their extraction results, settling any disagreements through dialogue and data cross-verification. STATA version 17.0 software (Stata Corp., College Station, TX) was used to conduct the meta-analysis. The pooled prevalence of hyperuricemia was calculated, along with its point estimate and 95% confidence interval. The pooled prevalence of hyperuricemia was estimated using a random-effects model of analysis [27]. Cochrane’s Q test and I2 statistics were used to assess heterogeneity between studies [28], in which an I2 of more than 75% was considered substantial heterogeneity. A p value of > 0.05 was used to declare that the effect was homogeneous. Subgroup analysis was used to determine the source of the heterogeneity, which was calculated based on the study participants’ age, sex, area, and population type. Lastly, a leave-one-out analysis was used in a sensitivity analysis to see how specific studies affected the overall pooled estimate of hyperuricemia. Additionally, publication bias was evaluated using Egger’s test statistics and visual examination of the funnel plot’s symmetry [29–31]. Additional study-level methodological features were retrieved and descriptively summarized to investigate potential sources of heterogeneity. These included laboratory assay methods, fasting status of participants during blood sample collection, and diagnostic cut-off values utilized to identify hyperuricemia. Even though all the included studies used the enzymatic uricase method to measure serum uric acid, cut-off values varied, especially among male participants, and there were some changes in clinical and laboratory procedures between researches. These factors were evaluated qualitatively when interpreting the results since they were thought to be possible causes of between-study variability. Results Description of eligible studies From a total of 69 articles found during the first electronic search and manual search of reference lists, 31 removed due to duplication then 30 were eliminated after full text revision. Eight papers were ultimately included in the final analysis following methodological quality assessment (Fig. 1). Flow diagram for the selection process of eligible studies Characteristics of included studies The studies included in this SRMA were conducted from 2017 to 2024 in four national regional states of Ethiopia. All studies were cross-sectional, and all are published in English. All studies employed enzymatic method (uricase enzyme) for the determination of serum uric acid level from fasting blood. In all the studies included in the systematic review, a total of 2292 patients with non-communicable diseases were involved. From the total participants 567 were CVDs, 1207 T2DM and 518 Hypertensive patients. Regarding their sex, 1283 participants were female and 1009 were males. Around 826 participants were less than or equal to 45 years and the remaining 1466 had age of greater than 45 years. From the included participants, 790 patients were reported to have increased serum uric acid. The highest prevalence of hyperuricemia (43.12%) was reported from Ambo, Oromia national regional state in 2024 and the lowermost prevalence (21.95%) was reported from Jimma in the same regional state. In terms of quality, six studies have Very good quality, and the remaining two studies have good quality. Variability was noted in clinical procedures and diagnostic thresholds, despite the enzymatic uricase technique being used consistently in all included trials. Three research used comparatively higher cut-off values for males, despite many studies defining hyperuricemia as serum uric acid levels > 7.0 mg/dL in males and > 6.0 mg/dL in females. Although fasting blood samples were used in all the studies, there was little information provided about sample handling techniques and device calibration. The residual heterogeneity seen in pooled results could be partially explained by these methodological variations (Table 1). Table 1Characteristics of included studies for assessing the epidemiology of hyperuricemia on patients with non-communicable diseases in EthiopiaAuthors and YearStudy periodRegionStudy DesignStudy GroupFasting statusSample sizeMale (n)Female (n)≤ 45 years> 45 yearsCut-off (mg/dl)Hyperuricemia casesPrevalenceQuality of the studyMaleFemaleBedasa et al., 2024 [32]June - September, 2022OromiaCSCVDsFasting269153116841857.06.0116 43.12 Very GoodNegese et al., 2025 [33]October, 2023-January, 2024OromiaCSCVDsFasting2981241741331657.06.0123 41.27 Very GoodOman et al., 2022 [34]January 2020-February 2021AmharaCSHTNFasting248108140352137.06.0105 42.33 GoodAbebe et al., 2021 [35]November -February, 2021Central EthiopiaCSHTNFasting2701391311311397.26.074 27.40 GoodBelete et al., 2019 [36]February-March, 2018AmharaCST2DMFasting384132152463387.06.0121 31.51 Very GoodSeid et al., 2025 [37]March -May, 2024Central EthiopiaCST2DMFasting22212795172507.06.082 36.93 Very GoodShiferaw et al., 2017 [38]February - May, 2017Southern Nations, Nationalities and PeoplesCST2DMFasting3142111031201947.26.0106 33.75 Very GoodKumsa et al., 2019 [39]March - June, 2019OromiaCST2DMFasting287189981051827.26.063 21.95 Very GoodCS: Cross-sectional, CVDs: Cardiovascular diseases, HTN; Hypertension, T2DM; Type 2 diabetes mellitusVery Good: average quality score of ≥ 75% and Good: average quality score of ≥ 50%. Characteristics of included studies for assessing the epidemiology of hyperuricemia on patients with non-communicable diseases in Ethiopia CS: Cross-sectional, CVDs: Cardiovascular diseases, HTN; Hypertension, T2DM; Type 2 diabetes mellitus Very Good: average quality score of ≥ 75% and Good: average quality score of ≥ 50%. Pooled prevalence of hyperuricemia among patients with NCDs in Ethiopia The prevalence of hyperuricemia among patients with non-communicable diseases ranges from the lowest 21.95% (95% CI; 17.6% – 26.74%) to 43.12% (95% CI; 37.2% – 49.04%). The random-effect model analysis revealed that the overall pooled prevalence of hyperuricemia among patients with non-communicable diseases in Ethiopia to be 34.64% (95% CI; 29.27% – 40.02%). There was a high level of heterogeneity with I2 value of (87.21%, p < 0.001) and Q test (Tau squared = 52.23, p < 0.001) (Fig. 2). Forest plot showing the prevalence of hyperuricemia among patients with NCDs in Ethiopia Subgroup analysis The random effect model revealed a high level of heterogeneity with I2 value of (87.21%, p < 0.001) and Q test (Tau squared = 52.23, p < 0.001). Therefore, subgroup analysis was performed by region where studies conducted, Sex, age group and study population type. Hyperuricemia by sex of the study participants Results from subgroup analysis by sex of the study participants revealed the pooled prevalence of hyperuricemia among female and male patients with NCDs were 34.71% (95% CI: 27.79, 41.63) and 34.51% (95% CI: 29.91, 39.10) respectively. A high level of heterogeneity was observed in female study participants with I2 of 82.63% while there was no heterogeneity in male study participants with I2 of 6.72% (Fig. 3). Forest plot showing the prevalence of hyperuricemia among patients with NCDs by sex Hyperuricemia by disease type of the study participants In addition, subgroup analysis by the type of NCD the patients had revealed that the highest prevalence of hyperuricemia was found to be on patients with CVDs (42.15% (95% CI: 38.08, 46.21)), followed by hypertensive patients (34.79% (95% CI: 20.16, 49.42)) and T2DM patients (30.87% (95% CI: 24.54, 37.20)). The CVDs sub group has zero degree of heterogeneity with I2 of 0.00% while a high level of heterogeneity was found in both the T2DM and hypertensive patients with I2 of 83.15% and 92.28% respectively (Fig. 4). Forest plot showing the prevalence of hyperuricemia among patients with NCDs by disease type Hyperuricemia by age of the study participants Prevalence of hyperuricemia was determined among study participants with different age group. The prevalence of hyperuricemia was 27.33% (95% CI: 19.82, 34.85) and 39.68% (95% CI: 34.08, 45.29) among study groups with age < 45 years and ≥ 45 years respectively. Significant level of heterogeneity was observed in age group < 45 years with I2 of 84.30% while level of heterogeneity was low among participants having age of ≥ 45 years with I2 of 33.33% (Fig. 5). Forest plot showing the prevalence of hyperuricemia among patients with NCDs by Age Publication bias To identify the presence of publication bias, funnel plot was plotted and showed asymmetrical distribution of studies around the 95% CI line (Fig. 6). The plotted graph was prone to subjectivity during examination and Egger’s test statistics confirmed the presence of publication bias with a p value of 0.0075. Thus, the non-parametric trim and fill analysis was performed using Fixed effect model to ensure stability of imputed studies. One additional article was imputed in the analysis, yielding the total number of articles to be 9 with a pooled prevalence of 32.546% (30.73%, 34.37%) (Table 2). The new pooled prevalence was not significantly different from the initial pooled prevalence. Funnel plot for studies on hyperuricemia among patients with NCDs in Ethiopia Table 2Non-parametric trim and fill analysis of studies to assess publication biasStudiesNumber of StudiesEffect size (95% CI)Model usedObserved834.644% (29.27, 40.018)Random effectImputed1Observed + Imputed932.546% (30.727, 34.365)Fixed effect Non-parametric trim and fill analysis of studies to assess publication bias Sensitivity analysis Since all recalculated prevalences stayed within the primary analysis’s 95% confidence interval, sensitivity analysis using the leave-one-out method showed that no single study had a disproportionate impact on the total pooled estimate. This result validates the pooled estimate’s robustness. Further evidence that the observed heterogeneity was not caused by single research but rather represents true variability across studies came from the between-study variance (τ²), which was comparatively constant during iterations. (Table 3; Fig. 7). Table 3Sensitivity analysis of studies on prevalence of hyperuricemia among patients with NCDsOmitted StudyEstimate95% CIP valueBedasa et al., 202433.4527.96–38.93 < 0.001 Negese et al., 202533.6927.99–39.40Oman et al., 202233.5727.96–39.19Abebe et al., 202135.6929.82–41.56Belete et al., 201935.1428.83–41.44Seid et al., 202534.3428.32–40.36Shiferaw et al., 201734.7928.55–41.03Kumsa et al., 201936.4631.97–40.92Overall 34.64 29.27–40.02 Sensitivity analysis of studies on prevalence of hyperuricemia among patients with NCDs Sensitivity Forest plot to show the effect of each study on the pooled estimate of hyperuricemia Discussion This systematic review and meta-analysis aimed to determine the pooled prevalence of hyperuricemia on patients with non-communicable diseases specifically; cardiovascular disorders, type 2 diabetes mellitus and hypertension. The burden of morbidities and mortalities related with CVDs, T2DM and hypertension is significantly high globally and reported to have an increased health effect in sub Saharan Africa [2]. The increased burden of these NCDs driven by increasing incidence of risk factors such as unhealthy diets, reduced physical activity, hypertension, obesity, diabetes, dyslipidemia, and air pollution [2, 3]. The difference in pre-analytical procedures including instrument calibration, study setting and recruitment method of study units might affect the overall pooled estimates of hyperuricemia reported by each study. Majority of the studies included for this meta-analysis defined hyperuricemia as serum uric acid > 7.0 mg/dL for males and > 6 mg/dL for females. Slightly higher cut off were used by three studies to define hyperuricemia among male study participants while similar definition for females [35, 38, 39]. These three studies were conducted on patients with T2DM and HTN where metabolic syndrome was a confounding health issue which increased the cut of value for uric acid higher than among males [40, 41]. The prevalence of hyperuricemia among patients with non-communicable diseases in Ethiopia ranged from the lowest 21.95% (95% CI; 17.6% – 26.74%) to 43.12% (95% CI; 37.2% – 49.04%). The random-effect model analysis revealed that the overall pooled prevalence of hyperuricemia among patients with non-communicable diseases in Ethiopia to be 34.64% (95% CI; 29.27% – 40.02%). The prevalence of hyperuricemia among patients with NCDs was found to be higher than the prevalence of hyperuricemia reported among healthy individuals in Addis Ababa, Ethiopia in 2021 (31%, 95% CI: 26.5–35.8) and the highest prevalence of hyperuricemia in Sub-Saharan Africa reported in 2024 (11.84%) [42, 43]. The current finding is also considerably higher than the figures reported among the general population from different parts of the world including China (11.1% (95% CI: 10.3%, 11.8%) in 2015–16 and 14.0% (95% CI: 13.1%, 14.8%) in 2018–19)), Korea (11.4%) in 2018, Seychelles (21.9%) in 2004, United States of America (14.6%) in 2019, Saudi Arabia (11.9%) in 2020 and Australia (16.6%) in 2016 [44–49]. On the other hand the prevalence reported in this meta-analysis was comparable with the prevalence of hyperuricemia reported among healthy individuals in Nigeria in 2015 (35.8%) [50]. Despite the presence of varying genetic predispositions, lifestyle factors (diet, alcohol, smoking), obesity rates, metabolic syndrome prevalence, and diagnostic criteria for hyperuricemia, the high prevalence reported in this study might solely dependent on the disease nature of study participants in the studies included in the current meta-analysis. This contradiction strongly supports the pathological role of increased uric acid for the onset and progression of non-communicable diseases. The high level of heterogeneity observed in the random effect meta-analysis of effect sizes might be caused by the difference of included studies in age range of the participants included for each study, sex of participants and the type of non-communicable disease the study specifically focused on. The subgroup analysis revealed statistically significant different prevalence of hyperuricemia by age and disease type. The pooled prevalence of hyperuricemia among patients with CVDs was significantly higher (42.15%, 95% CI: 38.08, 46.21), followed by hypertensive patients (34.79%, 95% CI: 20.16, 49.42) and T2DM patients (30.87%, 95% CI: 24.54, 37.20) (p = 0.01). This is in line with results from individual Ethiopian research, such as Bedasa et al., who found that the prevalence among cardiac patients was more than 43%. It is possible that underlying pathophysiological mechanisms account for this increased burden. Anaerobic metabolism is encouraged by decreased tissue perfusion and ischemia in cardiovascular circumstances, which increases the formation of lactate. By competing with uric acid for renal tubular excretion, elevated lactate lowers uric acid clearance and raises serum levels. Furthermore, oxidative stress and chronic inflammation, which are characteristics of cardiovascular disease, increase xanthine oxidase activity, which raises the generation of uric acid. Additionally, research points to a dose-response association between serum uric acid levels and cardiovascular risk, with increasing uric acid concentrations linked to greater endothelial dysfunction and a larger chance of unfavorable cardiovascular events [23]. The pooled prevalence of hyperuricemia among T2DM patients observed in this meta-analysis (30.87%, 95% CI: 24.54, 37.20) was significantly higher than the pooled prevalence of hyperuricemia among T2DM patients in Africa (27.28%, 95% CI: 23.07, 31.49) and East Africa (26.95%, 95% CI: 20.08, 38.83) reported in 2022 [51]. This contradiction might be due to Ethiopia’s unique combination of rapid lifestyle changes, dietary patterns, increased organ impairment and high metabolic burden which collectively pushes the prevalence above the continental average [52, 53]. Prevalence of hyperuricemia was determined among study participants with different age group. The prevalence of hyperuricemia was significantly higher among study groups with age ≥ 45 years (39.68%, 95% CI: 34.08, 45.29) than those aged < 45 years (27.33%, 95% CI: 19.82, 34.85) respectively (p = 0.01). This is most probably due to factors like hormonal shifts like menopause in women, kidney function decline leading to impaired clearance of uric acid, increased metabolic syndrome, lifestyle and socioeconomic factors, and medication use; which accumulate over time, while younger adults might have lower baseline risks [5]. The high level of heterogeneity (I² = 87.21%) persisted even after subgroup analyses by age, sex, and disease type, indicating the presence of additional unexplained variability. Variations in the diagnostic cut-off values for hyperuricemia, small inconsistencies in laboratory techniques, and variations in participant clinical profiles are some of the study-level methodological variables that could be responsible for this residual variability. Three research used comparatively higher cut-off values for males, which may have affected prevalence estimates, even though all investigations used fasting blood samples and the uricase enzymatic technique. Furthermore, true comparability between research is hampered by limited reporting of laboratory calibration processes and sample handling protocols. These differences in methodology probably led to the observed variability. The presence of publication bias was suggested by the asymmetrical funnel plot and further supported by Egger’s regression test (p = 0.0075). A non-parametric trim-and-fill analysis was carried out to take this into consideration. The robustness of the results was demonstrated by the adjusted pooled prevalence (32.55%, 95% CI: 30.73–34.37), which stayed like the initial random-effects estimate (34.64%). In accordance with normal implementation in statistical software (such as STATA), where fixed-effects assumptions are usually applied during imputation, the trim-and-fill process was carried out using a fixed-effects model. Due to the near alignment of both estimates, which supports the stability of the overall result, this methodological decision has no significant impact on the interpretation. This meta-analysis has some strengths and limitations. The study was the first to determine the true pooled prevalence of hyperuricemia among patients with non-communicable diseases in Ethiopia. The systematic review and meta-analysis followed the PRISMA guidelines appropriately and subgroup analysis was performed (by sex of participants, disease type and age of participants); these are considered as the strengths of this study. Moreover, the study has limitations like exclusion of articles published in languages other than English, high degree of heterogeneity even after subgroup analysis which reflects high level of difference among different studies included in this study. There is no study that used research design other than cross-sectional with which makes the relationship between hyperuricemia and NCDs temporal only. Finally, confounding variables like renal function, urate-lowering therapy and diuretic medications were not adjusted and reported uniformly in all studies which might influenced hyperuricemia estimate. Conclusion This systematic review and meta-analysis showed a high prevalence of hyperuricemia among patients with NCDs. Regular screening and monitoring of serum uric acid levels are recommended in patients with non-communicable diseases to mitigate its pathological effects and reduce the risk of disease progression and complications. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements The authors acknowledge all scholars and study participants whose researches were included in this meta-analysis. We also acknowledge all who give their help throughout this work. Abbreviations Non-communicable diseases Cardiovascular diseases Type 2 diabetes mellitus Serum uric acid Systematic review and meta-analysis Author contributions Afewerk Habtamu designed and conceptualized the study and search for articles, checked eligibility, performed data extraction, performed statistical analysis and prepared the manuscript. Zewudu Mulatie, Mikiyas Shemelis Achame, Sisay Desale, Saleamlak Sebsibe, Yonas Erkihun., Yeshimebt Kassa, Tesfaye Gessese, Mahider Shimelis Feyisa, Mihreteab Alebachew, and Bruktawit Eshetu Significantly contributed in searching articles, screening and extracting data, assessing the quality of included data. Furthermore, they involved in the statistical analysis and reviewing, and editing the manuscript. Funding No funding was obtained from anybody for this systematic review and meta-analysis. Data availability The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.